-ast
Anti-allergy or anti-inflammatory drugs that work without blocking histamine.
- Drugs ending in -ast: 36
- Approved somewhere: 8
- With a US drug page: 8
- Stem
- -ast
- Class
- Anti-allergy or anti-inflammatory drugs that work without blocking histamine
- Most common targets
- Phosphodiesterase 4 (12), CYSLTR1 (3), ITGAL, ITGB2 (1), PDE3A (1), PDE10A (1), PDE5A (1), ITGA4, ITGB1 (1), ITGA4, ITGB7 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -ast or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Lifitegrast | Approved | ITGAL, ITGB2 | Integrin alpha-L/beta-2 (LFA-1) antagonist |
| Pemirolast | Phase 2 | — | Unknown |
| Ibudilast | Approved | Phosphodiesterase 4, PDE3A, PDE10A, PDE5A | Phosphodiesterase 4 inhibitor |
| Tranilast | Phase 3 | — | — |
| Asengeprast | Phase 2 | — | — |
| Bexotegrast | Phase 2 | — | — |
| Firategrast | Phase 2 | ITGA4, ITGB1, ITGA4, ITGB7 | Integrin alpha-4/beta-1 antagonist |
| Nesvategrast | Phase 2 | — | — |
| Ofirnoflast | Phase 2 | — | — |
| Usnoflast | Phase 2 | — | — |
| Valategrast | Phase 2 | — | — |
| Fibroblast growth FACTOR-1 | Phase 1 | — | — |
| Selnoflast | Phase 1 | — | — |
| Andolast | — | KCNMA1 | Calcium-activated potassium channel subunit alpha-1 activator |
| Montelukast | Approved | CYSLTR1 | Cysteinyl leukotriene receptor 1 antagonist |
| Zafirlukast | Approved | CYSLTR1 | Cysteinyl leukotriene receptor 1 antagonist |
| Pranlukast | Approved | CYSLTR1 | Cysteinyl leukotriene receptor 1 antagonist |
| Gemilukast | Phase 2 | — | — |
| Tipelukast | Phase 2 | — | — |
| Apremilast | Approved | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Roflumilast | Approved | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Difamilast | Phase 3 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Nerandomilast | Phase 2 | — | — |
| Cilomilast | Phase 3 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Mufemilast | Phase 3 | — | — |
| Tetomilast | Phase 3 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Zatolmilast | Phase 3 | PDE4D | Phosphodiesterase 4D inhibitor |
| Dovramilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Lotamilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Oglemilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Orismilast | Phase 2 | — | — |
| Revamilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Tofimilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Tranimilast | Phase 2 | Phosphodiesterase 4 | Phosphodiesterase 4 inhibitor |
| Idrebormilast | Phase 1 | — | — |
| Seratrodast | Approved | TBXA2R | Thromboxane A2 receptor antagonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO